Summit Trail Advisors LLC Sells 436 Shares of Becton, Dickinson and Company (NYSE:BDX)

Summit Trail Advisors LLC reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,325 shares of the medical instruments supplier’s stock after selling 436 shares during the quarter. Summit Trail Advisors LLC’s holdings in Becton, Dickinson and Company were worth $323,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. OFI Invest Asset Management bought a new position in shares of Becton, Dickinson and Company in the third quarter worth $25,000. DiNuzzo Private Wealth Inc. purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth about $30,000. Fortitude Family Office LLC bought a new position in Becton, Dickinson and Company in the 4th quarter worth about $35,000. Venturi Wealth Management LLC grew its holdings in Becton, Dickinson and Company by 552.0% during the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 138 shares in the last quarter. Finally, Arlington Trust Co LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at about $41,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.2 %

BDX stock opened at $237.15 on Wednesday. The business’s 50 day moving average price is $238.27 and its two-hundred day moving average price is $239.97. The company has a market capitalization of $68.54 billion, a price-to-earnings ratio of 52.23, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.86 earnings per share. As a group, analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Analysts Set New Price Targets

Separately, Barclays raised their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $281.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.